Post-market review of spinal cord stimulator devices
Published
Related content
-
TGA confirms decision to not register lecanemab (LEQEMBI)
Following a request from the sponsor to reconsider their decision, the TGA has confirmed the initial decision to not register the medicine on the basis that the safety and efficacy of the medicine were not satisfactorily established. -
Post-market review of facemasks closed
The COVID-19 pandemic post-market review of facemasks is now finished. -
TGA's decision to not register lecanemab (LEQEMBI)
TGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease).